GlassScriptPhysician profile
Newton B Coutinho
NPI 1124077334
$9,824.41
in general payments reported to CMS, 2019-2025
29 companies · $834 in 2025
The $834 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,135 · 2020: $2,638 · 2021: $423 · 2022: $248 · 2023: $901 · 2024: $646 · 2025: $834.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,925 · Debt Forgiveness: $456.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,924.86 |
| Debt Forgiveness | $456.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,249.42 | 2019-2025 | Farxiga |
| Medtronic Vascular, INC. | $2,107.71 | 2019 | |
| Pfizer INC. | $960.00 | 2019-2021 | |
| Amgen INC. | $667.75 | 2019-2025 | Repatha, Repatha |
| Medtronic, INC. | $612.85 | 2023-2025 | Azure Xt Dr Mri Surescan, Aurora Ev-Icd Mri Surescan, Cobalt Dr Mri Surescan |
| Bayer Healthcare Pharmaceuticals INC. | $558.54 | 2023-2025 | |
| Lantheus Medical Imaging, INC. | $456.00 | 2023 | Definity |
| Glaxosmithkline, LLC. | $357.63 | 2019-2025 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $297.46 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $240.25 | 2019-2025 | Ozempic |
| E.R. Squibb & Sons, L.L.C. | $202.46 | 2019-2025 | Camzyos |
| Esperion Therapeutics, INC. | $178.94 | 2021 | |
| Janssen Pharmaceuticals, INC | $176.43 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $109.35 | 2019 | |
| Sanofi-Aventis U.S. LLC | $90.71 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $73.42 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $64.89 | 2020-2023 | |
| Lundbeck LLC | $63.37 | 2019-2020 | |
| Amarin Pharma, INC. | $53.57 | 2020-2021 | |
| Kiniksa Pharmaceuticals, LTD. | $52.17 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $48.69 | 2024-2025 | Opsumit, Uptravi |
| Baxter Healthcare | $47.39 | 2022-2025 | Hillrom - Cardiac Ambulatory Monitor |
| Boston Scientific Corporation | $41.37 | 2023 | Lux-Dx Insertable Cardiac Monitor, Lithovue |
| Preventice Services, LLC | $27.78 | 2019 | |
| Merck Sharp & Dohme LLC | $23.30 | 2019-2021 | |
| Lilly USA, LLC | $17.89 | 2025 | Mounjaro |
| Alnylam Pharmaceuticals INC. | $17.22 | 2025 | Amvuttra |
| Abiomed | $15.67 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $12.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Newton Coutinho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.